| Literature DB >> 33402704 |
Dirk Roosterman1, Graeme Stuart Cottrell2.
Abstract
Schizophrenia is a chronic and severe mental disorder that affects over 20 million people worldwide. Common symptoms include distortions in thinking, perception, emotions, language, and self awareness. Different hypotheses have been proposed to explain the development of schizophrenia, however, there are no unifying features between the proposed hypotheses. Schizophrenic patients have perturbed levels of glucose in their cerebrospinal fluid, indicating a disturbance in glucose metabolism. We have explored the possibility that disturbances in glucose metabolism can be a general mechanism for predisposition and manifestation of the disease. We discuss glucose metabolism as a network of signaling pathways. Glucose and glucose metabolites can have diverse actions as signaling molecules, such as regulation of transcription factors, hormone and cytokine secretion and activation of neuronal cells, such as microglia. The presented model challenges well-established concepts in enzyme kinetics and glucose metabolism. We have developed a 'two-cell' model of glucose metabolism, which can explain the effects of electroconvulsive therapy and the beneficial and side effects of olanzapine treatment. Arrangement of glycolytic enzymes into metabolic signaling complexes within the 'two hit' hypothesis, allows schizophrenia to be formulated in two steps. The 'first hit' is the dysregulation of the glucose signaling pathway. This dysregulation of glucose metabolism primes the central nervous system for a pathological response to a 'second hit' via the astrocytic glycogenolysis signaling pathway.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33402704 PMCID: PMC8440173 DOI: 10.1038/s41380-020-00980-4
Source DB: PubMed Journal: Mol Psychiatry ISSN: 1359-4184 Impact factor: 13.437
Fig. 1Hypothetical flow of glucose in the brain.
The concentration of glucose in the interstitial fluid is low (2.6 mM) [23] and insufficient to supply neuronal compartments of high-energy demand. Astrocytic endfeet completely cover capillaries, where the concentration of glucose is high (5.5 mM) [25]. Glucose is transported via glucose transporters (GLUTs) from the blood stream, across the astrocyte and delivered to neuronal compartments of high-energy demand via astrocytic and neuronal GLUTs. Astrocytic glycogenolysis is a signaling pathway producing glucose, which enters the glucose transit pathway and glucose-1-phosphate. The latter is converted to glucose-6-phosphate, which inhibits hexokinase II [73], thereby blocking astrocytic glycolysis. Decreased astrocytic glycolysis further increases the availability of glucose for neuronal transit. A ‘tightly’ regulated astrocyte-neuron compartment ensures delivery of glucose to the neuron and keep microglial cells in a ‘quiescent’ state. In contrast, a ‘compromised’ astrocyte-neuron compartment, perhaps due to the altered expression of stabilizing genes, genetic variations, or epigenetic modifications, may lead to glucose ‘leakage’, promoting formation of a glucose gradient and subsequent microglial activation.
Fig. 2The ‘sending’ and ‘receiving’ of signals via glucose metabolism.
a Glucose, taken up via glucose transporters (GLUTs) and produced by the breakdown of glycogen (glycogenolysis) is exported as a signal via GLUTs. In addition, glucose is converted to pyruvate (pyr−) and lactate (l-lac−) via glycolysis and exported as pyruvic acid (pyrH) and lactic acid (l-lacH) via the proton-linked monocarboxylate transporter 4 (MCT4)•phosphoglycerate kinase (PGK) complex [35]. b Pyr− and l-lac- are imported as pyrH and l-lacH into the cell via the MCT1•carbonic anhydrase II (CAII) complex [35]. A cytosolic muscle lactate dehydrogenase (LDH-m)•proton donor (PD) complex converts pyruvate (pyr−) to lactate (l-lac−) and a cytosolic heart LDH (LDH-m)•proton acceptor (PA) complex converts lactate (l-lac−) to pyruvate (pyr−). Alternatively, l-lac− is converted to pyr− by the proton-linked mitochondrial MCT1•LDH-h complex to fuel the l-lac−-tricarboxylic acid (TCA)/electron transport chain (ETC) cycle [35]. Pyr− is transported into the mitochondrial matrix via the mitochondrial pyr− carrier (MPC) to power the pyr−-TCA cycle [35] tit. A violet H+ indicates the H+ is part of a proton-coupled reaction. The blue H+ indicated on the pyrH transferred by the MPC, comes from the mitochondrial matrix.
List of gene and common protein names and abbreviations.
| Gene name | Common protein name | Abbreviation in text |
|---|---|---|
| Carbonic anhydrase II | CAII | |
| Glyceraldehyde 3-phosphate dehydrogenase | GAPDH | |
| Hexokinase II | None | |
| Muscle lactate dehydrogenase | LDH-m | |
| Heart lactate dehydrogenase | LDH-h | |
| Phosphoglycerate kinase | PGK | |
| Monocarboxylate transporter 1 | MCT1 | |
| Monocarboxylate transporter 4 | MCT4 | |
| Monocarboxylate transporter 2 | MCT2 | |
| Na+/H+ exchanger 1 | None | |
| Na+/H+ exchanger 2 | None | |
| Na+/H+ exchanger 3 | None |